Results 61 to 70 of about 2,147 (178)

Biologics and Small‐Molecule Therapies in Netherton Syndrome: A Comprehensive Review

The Journal of Dermatology, Volume 52, Issue 10, Page 1483-1493, October 2025.
ABSTRACT Netherton syndrome (NS) is a rare congenital ichthyosis caused by loss‐of‐function mutations in the SPINK5 gene, leading to defective expression of the serine protease inhibitor LEKTI. Dysregulated epidermal protease activity results in impaired skin barrier function and chronic inflammation, accompanied by complex immune profiles. NS patients
Shin Morizane, Tomoyuki Mukai, Ko Sunagawa, Ken‐ichi Hasui, Anri Morita, Hayato Nomura, Mamoru Ouchida   +6 more
wiley   +1 more source

From Bench to Clinic: Advances in Anti‐Inflammatory Therapies for Atherosclerotic Coronary Artery Disease

The FASEB Journal, Volume 39, Issue 18, 30 September 2025.
The changing face of AS. This diagram illustrates the research landscape of ASCAD. It highlights a shift in understanding from viewing it as a lipid storage disease to recognizing it as a chronic inflammatory disease. Additionally, emerging therapies like colchicine, methotrexate, IL‐1 blockade, IL‐6 blockade, darapladib, and low‐dose IL‐2 are being ...
Kan Wang, Zheng Yin, Yang Zhang, Xianpeng Wu, Lin Fan   +4 more
wiley   +1 more source

Interleukin-1: from discovery to therapeutic targeting of the first cytokine

Allergology International
Interleukin-1 (IL-1) was the first cytokine to be discovered and remains one of the most instructive molecules in immunology, linking fundamental mechanisms of innate immune activation to human inflammatory disease and targeted therapy.
Lori Broderick, Naotomo Kambe, Hal M. Hoffman   +2 more
doaj   +1 more source

Cytokine Engineering Approaches for Regenerative Medicine

Advanced Therapeutics, Volume 8, Issue 9, September 2025.
Engineered cytokines represent a powerful strategy to promote tissue repair and regeneration by precisely modulating immune responses. This review highlights recent advances in cytokine engineering, including strategies to enhance half‐life, improve tissue and cell targeting, and control receptor signaling.
Shiyi Li, Wenhao You, Mikaël M. Martino
wiley   +1 more source

RHAPSODY : Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis

, 2020
Recurrent pericarditis (RP) occurs in 15% to 30% of patients following a first episode, despite standard treatment with nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids; many patients become dependent on corticosteroids.
Perrin R., Gervais A., Fang F., Beutler A., Abbate A., Paolini J. F., Cremer P., Lin D., Imazio M., Martini A., Klein A. L., Brucato A., LeWinter M., Chang S.   +13 more
core   +1 more source

Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts

Arthritis Research & Therapy, 2019
Background Adult-onset Still’s disease (AOSD) is a rare inflammatory condition characterized by fever, rash, and arthritis. Because of its rarity, clinical trials are inherently small and often uncontrolled.
Serena Colafrancesco, Maria Manara, Alessandra Bortoluzzi, Teodora Serban, Gerolamo Bianchi, Luca Cantarini, Francesco Ciccia, Lorenzo Dagna, Marcello Govoni, Carlomaurizio Montecucco, Roberta Priori, Angelo Ravelli, Paolo Sfriso, Luigi Sinigaglia, AOSD Consensus Group   +14 more
doaj   +1 more source

Dehydrocostus Lactone Effectively Alleviates Inflammatory Diseases by Covalently and Irreversibly Targeting NLRP3

MedComm, Volume 6, Issue 9, September 2025.
Dehydrocostus lactone (DCL) covalently binds to NLRP3 and effectively reduces the interaction between NEK7 and NLRP3, thereby blocking the assembly of NLRP3 inflammasome complex and subsequent activation in macrophages. Consequently, DCL inhibits the cleavage and maturation of pro‐IL‐1β and pro‐IL‐18, ultimately leading to the suppression of the ...
Qi Lv, Yishu Zhang, Juan Wang, Weijiang Lin, Ying Xie, Hongqiong Yang, Xunkai Yin, Zhenzhen Zhu, Yifan Cui, Yang Hu, Li Zeng, Yinan Zhang, Xubing Chen, Jian Liu, Lihong Hu   +14 more
wiley   +1 more source

The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives

Drug Design, Development and Therapy, 2018
Nataša Toplak,1,2 Štefan Blazina,1 Tadej Avčin1,2 1Department of Allergology, Rheumatology and Clinical Immunology, University Children’s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia; 2Faculty of Medicine ...
Toplak N, Blazina Š, Avčin T
doaj  

Effusive Constrictive Pericarditis in the Era of COVID-19

Annals of Internal Medicine: Clinical Cases
Effusive-constrictive pericarditis is a rare condition in which the visceral pericardium compresses the heart, with fluid accumulation in the pericardial space leading to cardiac tamponade.
Shriya Sharma, Si Pham, Archer Martin, Jose Ruiz, Caitlyn Luce, Aarti Desai, Rohan M. Goswami   +6 more
doaj   +1 more source

IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus

Frontiers in Pharmacology, 2017
Diabetes mellitus (DM) is a chronic disease that affects nowadays millions of people worldwide. In adults, type 2 diabetes mellitus (T2DM) accounts for the majority of all diagnosed cases of diabetes.
Concepción Peiró, Concepción Peiró, Óscar Lorenzo, Óscar Lorenzo, Raffaele Carraro, Raffaele Carraro, Raffaele Carraro, Carlos F. Sánchez-Ferrer, Carlos F. Sánchez-Ferrer   +8 more
doaj   +1 more source